Browse by author
Lookup NU author(s): Dr Catherine Napier, Professor Simon PearceORCiD
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Purpose of reviewThe purpose of this article is to review the current therapy of Addison's disease and to highlight recent developments in this field.Recent findingsConventional steroid replacement for Addison's disease consists of twice or three-times daily oral hydrocortisone and once-daily fludrocortisone; however, new treatment modalities such as modified-released hydrocortisone and continuous subcutaneous hydrocortisone infusion have recently been developed. These offer the potential for closer simulation of the physiological serum cortisol rhythm. Two studies have also looked at modifying the natural history of adrenal failure using adrenocorticotropic hormone (ACTH) stimulation and immunomodulatory therapies, leading to the concept of residual adrenal function in some Addison's disease patients.SummaryFollowing more than 60 years with no significant innovation in the management of Addison's disease, these new approaches hold promise for improved patient health and better quality of life in the future.
Author(s): Napier C, Pearce SHS
Publication type: Review
Publication status: Published
Journal: Current Opinion in Endocrinology, Diabetes & Obesity
Year: 2014
Volume: 21
Issue: 3
Pages: 147-153
Print publication date: 01/06/2014
ISSN (print): 1752-296X
ISSN (electronic): 1752-2978
Publisher: LIPPINCOTT WILLIAMS & WILKINS
URL: http://dx.doi.org/10.1097/MED.0000000000000067
DOI: 10.1097/MED.0000000000000067